Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2491 to 2505 of 7687 results

  1. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]

    In development [GID-TA11369] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]

    In development [GID-TA11480] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome

    In development [GID-DG10074] Expected publication date: 19 December 2024

    Diagnostics guidance
    In development

  4. Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

    In development [GID-TA10165] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Spesolimab for treating generalised pustular psoriasis flares [ID3963]

    In development [GID-TA10871] Expected publication date: 19 March 2025

    Technology appraisal guidance
    In development

  6. Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating primary advanced or recurrent endometrial cancer ID6381

    In development [GID-TA11461] Expected publication date: 16 April 2025

    Technology appraisal guidance
    In development

  7. Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]

      Status ...

    Technology appraisal guidance
    Topic selection

  8. Molnupiravir for treating COVID-19 [ID6340]

    In development [GID-TA11409] Expected publication date: 29 January 2025

    Technology appraisal guidance
    In development

  9. Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: Late stage assessment

    In development [GID-HTE10027] Expected publication date: 08 January 2025

    Health technology evaluations
    In development

  10. Fruquintinib for previously treated metastatic colorectal cancer ID6274

    In development [GID-TA11280] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development

  11. Sparsentan for treating primary IgA nephropathy [ID6308]

    In development [GID-TA11359] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  12. Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over [ID6140]

    In development [GID-TA11062] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Cabotegravir for preventing HIV-1 in adults and young people [ID6255]

    In development [GID-TA11304] Expected publication date: 29 January 2025

    Technology appraisal guidance
    In development

  14. Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments [ID6325](review of TA677)

    In development [GID-TA11545] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  15. Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235

    In development [GID-TA11246] Expected publication date: TBC

    Technology appraisal guidance
    In development